What is Renovaro's earnings per share (EPS)?

Renovaro (RENB) reported diluted earnings per share of $-1.08 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Renovaro Financials

RENB

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE June

This page shows Renovaro (RENB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RENB FY2025 2026-04-22

Lunai Bioworks has become a liquidity-driven survival story, with cash burn easing mainly because spending was cut faster than obligations.

Operating cash burn improved across FY2023-FY2025, but R&D spending was cut even harder over the same span, so the smaller cash drain looks more like retrenchment than a business reaching self-support through its own operations. Cash was $93K against $29.2M of current liabilities, so the lower burn did not ease near-term funding pressure.

The FY2024 balance sheet was goodwill-heavy: goodwill alone was $159.3M out of $163.1M of assets, so the reported equity cushion depended far more on intangibles than on liquid resources. Later, asset shrinkage left total assets at $8.2M and equity at -$21.3M, showing how quickly that cushion disappeared.

Near-term liquidity tightened fast: cash fell from $1.9M to $93K over the last three valid years. With current liabilities still above $29M, day-to-day obligations appear to have depended on external financing rather than cash generated inside the business.

Financial Health Signals

Financial Profile 16/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Renovaro's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Renovaro carries a low D/E ratio of -1.39, meaning only $-1.39 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Renovaro's current ratio of 0.04 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-1.08

Renovaro earned $-1.08 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 18.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$93K

YoY-58.0%

5Y CAGR-59.7%

10Y CAGR-29.4%

Renovaro held $93K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

18M

Renovaro had 18M shares outstanding in fiscal year 2025. This represents a decrease of 88.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$537K

YoY-80.2%

5Y CAGR-35.2%

Renovaro invested $537K in research and development in fiscal year 2025. This represents a decrease of 80.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RENB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$537K-80.2%	$2.7M-35.0%	$4.2M-50.3%	$8.4M-46.7%	$15.7M+234.9%	$4.7M
SG&A Expenses	$17.9M-27.2%	$24.6M+60.3%	$15.3M+6.9%	$14.3M+89.6%	$7.6M+6.1%	$7.1M
Operating Income	N/A	-$81.6M-111.7%	-$38.6M+66.8%	-$116.1M-396.0%	-$23.4M-96.3%	-$11.9M
Interest Expense	$726K-28.2%	$1.0M+74.3%	$580K+55.7%	$373K-1.8%	$380K+264.0%	$104K
Income Tax	$1K	$0	N/A	$34+100.0%	-$125K	N/A
Net Income	N/A	-$88.4M-122.8%	-$39.7M+65.0%	-$113.4M-324.5%	-$26.7M-134.1%	-$11.4M
EPS (Diluted)	$-1.08	$-0.91-28.2%	$-0.71+67.1%	$-2.16	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$21K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$21K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$16K-65.2%	$46K+87.9%	$24K	N/A	N/A	$161K-58.7%	$390K	N/A
SG&A Expenses	$1.4M-19.5%	$1.8M-26.7%	$2.4M	N/A	$4.2M-3.0%	$4.4M-17.9%	$5.3M	N/A
Operating Income	-$1.5M+19.0%	-$1.8M+44.9%	-$3.3M	N/A	-$4.2M+8.4%	-$4.5M+91.5%	-$53.3M	N/A
Interest Expense	$108K-11.1%	$122K-0.7%	$122K	N/A	$189K+90.8%	$99K-60.5%	$250K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.6M-42.9%	-$1.8M-163.8%	$2.8M	N/A	$189K+102.6%	-$7.3M+83.6%	-$44.2M	N/A
EPS (Diluted)	$-0.10-25.0%	$-0.08	$0.13	N/A	$0.00+100.0%	$-0.45+83.7%	$-2.76	N/A

RENB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.2M-95.0%	$163.1M+179.8%	$58.3M-31.1%	$84.6M-55.4%	$189.6M+6.5%	$178.1M
Current Assets	$1.0M-47.6%	$2.0M-22.1%	$2.6M-73.2%	$9.6M-54.2%	$20.9M+133.7%	$8.9M
Cash & Equivalents	$93K-58.0%	$220K-88.2%	$1.9M-79.6%	$9.2M-55.6%	$20.7M+137.6%	$8.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$6.0M-96.3%	$159.3M+1268.8%	$11.6M0.0%	$11.6M0.0%	$11.6M0.0%	$11.6M
Total Liabilities	$29.6M-5.0%	$31.2M+164.0%	$11.8M-1.8%	$12.0M-19.6%	$14.9M+26.3%	$11.8M
Current Liabilities	$29.2M-3.8%	$30.3M+175.0%	$11.0M+70.9%	$6.5M+242.1%	$1.9M+41.3%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$21.3M-116.2%	$132.0M+183.8%	$46.5M-36.0%	$72.6M-58.4%	$174.7M+5.0%	$166.3M
Retained Earnings	-$510.5M-53.5%	-$332.5M-36.2%	-$244.0M-19.4%	-$204.3M-124.8%	-$90.9M-41.6%	-$64.2M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$9.9M+47.9%	$6.7M-4.2%	$7.0M-15.4%	$8.2M-93.0%	$117.7M+5.7%	$111.3M-8.6%	$121.8M-25.3%	$163.1M
Current Assets	$3.7M+625.5%	$514K-35.7%	$800K-23.5%	$1.0M-71.5%	$3.7M+114.7%	$1.7M-12.3%	$1.9M-2.5%	$2.0M
Cash & Equivalents	$3.2M+541.8%	$492K-21.3%	$625K+574.0%	$93K-90.0%	$923K+196.1%	$312K+41.3%	$221K0.0%	$220K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	$964K	N/A	N/A	N/A
Goodwill	$6.0M0.0%	$6.0M0.0%	$6.0M0.0%	$6.0M-94.7%	$112.6M+4.3%	$108.0M-8.6%	$118.2M-25.8%	$159.3M
Total Liabilities	$19.4M-4.0%	$20.2M+1.1%	$20.0M-32.4%	$29.6M+0.8%	$29.3M+0.2%	$29.3M+23.3%	$23.7M-23.8%	$31.2M
Current Liabilities	$19.3M-3.6%	$20.0M+1.4%	$19.7M-32.4%	$29.2M+1.1%	$28.8M+0.8%	$28.6M+24.2%	$23.0M-24.0%	$30.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$9.6M+29.5%	-$13.5M-3.9%	-$13.0M+38.9%	-$21.3M-124.2%	$88.4M+7.7%	$82.1M-16.3%	$98.1M-25.7%	$132.0M
Retained Earnings	-$512.0M-0.5%	-$509.4M-0.4%	-$507.6M+0.6%	-$510.5M-33.0%	-$383.7M0.0%	-$383.9M-1.9%	-$376.7M-13.3%	-$332.5M

RENB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.9M+28.2%	-$11.0M+6.8%	-$11.8M+25.2%	-$15.7M+23.7%	-$20.6M-97.1%	-$10.5M
Capital Expenditures	N/A	$70K+136.5%	$30K+477.5%	$5K-89.5%	$49K-73.5%	$184K
Free Cash Flow	N/A	-$11.0M+6.5%	-$11.8M+25.0%	-$15.7M+23.8%	-$20.7M-94.1%	-$10.6M
Investing Cash Flow	-$500K+60.3%	-$1.3M-4132.5%	-$30K-477.5%	-$5K+89.5%	-$49K+73.5%	-$184K
Financing Cash Flow	$8.4M-20.3%	$10.5M+132.9%	$4.5M+6.2%	$4.3M-87.0%	$32.6M+352.8%	$7.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$1.0M+4.1%	-$1.1M+20.6%	-$1.3M+25.5%	-$1.8M-21.8%	-$1.5M+41.9%	-$2.6M-26.9%	-$2.0M+16.5%	-$2.4M
Capital Expenditures	$0	N/A	N/A	N/A	N/A	N/A	N/A	$24K
Free Cash Flow	-$1.0M	N/A	N/A	N/A	N/A	N/A	N/A	-$2.4M
Investing Cash Flow	$0+100.0%	-$1K-100.2%	$545K-43.5%	$964K	N/A	N/A	$0+100.0%	-$53K
Financing Cash Flow	$3.7M+289.8%	$950K-29.3%	$1.3M+653.2%	$178K-95.0%	$3.6M+38.3%	$2.6M+27.7%	$2.0M-17.7%	$2.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RENB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-67.0%+18.3pp	-85.3%+70.9pp	-156.2%-140.9pp	-15.3%-8.4pp	-6.9%
Return on Assets	N/A	-54.2%+13.9pp	-68.1%+66.0pp	-134.0%-119.9pp	-14.1%-7.7pp	-6.4%
Current Ratio	0.04-0.0	0.07-0.2	0.23-1.3	1.48-9.6	11.08+4.4	6.70
Debt-to-Equity	-1.39-1.6	0.24-0.0	0.25+0.1	0.17+0.1	0.09+0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	100.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-7054.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-12278.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	0.2%+9.1pp	-8.8%+36.2pp	-45.1%	N/A
Return on Assets	-26.1%+0.9pp	-27.0%-67.5pp	40.5%	N/A	0.2%+6.7pp	-6.5%+29.8pp	-36.3%	N/A
Current Ratio	0.19+0.2	0.03-0.0	0.040.0	0.04-0.1	0.13+0.1	0.06-0.0	0.08+0.0	0.07
Debt-to-Equity	-2.03-0.5	-1.49+0.0	-1.53-0.1	-1.39-1.7	0.33-0.0	0.36+0.1	0.240.0	0.24
FCF Margin	-4903.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$21.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Radiopharm Theranostics Ltd RADX

$36.5M

Tempest Therapeutics Inc TPST

$27.5M

Acrivon Therapeutics, Inc. ACRV

$74.9M

Barinthus Biotherapeutics plc BRNS

$28.1M

Bioatla, Inc. BCAB

$6.1M

Frequently Asked Questions

What is Renovaro's operating cash flow?

Renovaro (RENB) generated -$7.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Renovaro's total assets?

Renovaro (RENB) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Renovaro spend on research and development?

Renovaro (RENB) invested $537K in research and development during fiscal year 2025.

How many shares does Renovaro have outstanding?

Renovaro (RENB) had 18M shares outstanding as of fiscal year 2025.

What is Renovaro's current ratio?

Renovaro (RENB) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Renovaro's debt-to-equity ratio?

Renovaro (RENB) had a debt-to-equity ratio of -1.39 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Renovaro's cash runway?

Based on fiscal year 2025 data, Renovaro (RENB) had $93K in cash against an annual operating cash burn of $7.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Renovaro's debt-to-equity ratio negative or unusual?

Renovaro (RENB) has negative shareholder equity of -$21.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Renovaro?

Renovaro (RENB) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.